Competitive watch
Who else is racing on non-opioid pain — mapped against DOL-001.
Non-opioid pain is saturated — Vertex opened the door with a NaV1.8 blocker, and China is lining up 7+ NaV programs. Dolinnov’s edge is FXYD2 (no equivalent target) delivered as a peripheral DRG ASO — neither a target me-too nor a modality me-too.
Head-to-head radar
DOL-001 leads on target novelty (FXYD2, no rival programme) and peripheral selectivity (DRG-restricted ASO).
The direct ASO / repressor rivals (Quiver, Sangamo) match on durability but sit on the crowded NaV1.7 target. Vertex leads only on clinical maturity — an approved NaV1.8 drug, a different target and modality.
Scored 1–5 from the profile set · see Method for the source doctrine.
Competitive table
Genetic medicines for pain — the real battlefield. Everyone who silences a pain gene (ASO, siRNA, epigenetic repressor, gene therapy). These are our most direct rivals; the rest of the field uses other modalities.
Positioning. Differentiation vs DOL-001 (Y) against clinical maturity (X), for the direct field (Tier 1 + high-relevance). Dolinnov sits clear: high differentiation, early stage.
Academic players. Labs and translational groups advancing the same biology — potential partners as much as competitors.
Deal mapping. What the non-opioid pain space is worth — licenses, acquisitions and rounds, newest first.
Tiers. Tier 1 — same modality: everyone silencing a pain gene (ASO, siRNA, epigenetic repressor, gene therapy) — our most direct rivals. Tier 2 — adjacent: non-opioid pain, other modalities (NaV small molecules, peptides, biologics). Tier 3 — broader: neighbouring indications/mechanisms (investor questions).
Source doctrine (decreasing reliability): scientific congresses / presentations > peer-reviewed publications & dated preprints (“to confirm”) > press releases / ClinicalTrials.gov / SEC / GlobalData > press & LinkedIn. Every profile carries a Confidence level.
Refresh. The data lives in the vault JSON (competitors.json / deals.json), the single source of truth; the page is regenerated from it — never edited by hand. Ask Claude to refresh when new trials, deals, rounds or publications land.